Oliver Luxxe Assets LLC Invests $1.47 Million in Ardent Health Partners, LLC (NYSE:ARDT)

Oliver Luxxe Assets LLC bought a new position in Ardent Health Partners, LLC (NYSE:ARDT) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 85,754 shares of the company’s stock, valued at approximately $1,465,000. Oliver Luxxe Assets LLC owned about 0.06% of Ardent Health Partners at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ARDT. Wellington Management Group LLP purchased a new stake in Ardent Health Partners during the 3rd quarter valued at about $28,724,000. Point72 Asset Management L.P. purchased a new position in shares of Ardent Health Partners in the third quarter valued at about $27,428,000. Goldentree Asset Management LP bought a new position in shares of Ardent Health Partners during the third quarter valued at about $22,897,000. Franklin Resources Inc. purchased a new stake in shares of Ardent Health Partners during the third quarter worth about $15,839,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Ardent Health Partners in the third quarter worth about $13,119,000.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ARDT shares. Truist Financial cut their price objective on Ardent Health Partners from $22.00 to $21.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $20.00 price objective on shares of Ardent Health Partners in a report on Tuesday, December 17th. Royal Bank of Canada reiterated an “outperform” rating and set a $23.00 price target on shares of Ardent Health Partners in a research report on Thursday, November 14th. Leerink Partners lifted their price objective on Ardent Health Partners from $23.00 to $25.00 and gave the company an “outperform” rating in a research report on Tuesday, November 12th. Finally, Morgan Stanley decreased their target price on Ardent Health Partners from $23.50 to $22.00 and set an “overweight” rating for the company in a research report on Tuesday. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $21.55.

Ardent Health Partners Trading Up 5.0 %

Shares of NYSE:ARDT opened at $15.27 on Friday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.91 and a quick ratio of 1.78. The company’s fifty day moving average is $16.11. Ardent Health Partners, LLC has a 12-month low of $13.63 and a 12-month high of $20.72.

Ardent Health Partners (NYSE:ARDT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.10). The company had revenue of $1.45 billion for the quarter, compared to the consensus estimate of $1.46 billion. Research analysts predict that Ardent Health Partners, LLC will post 1.22 earnings per share for the current fiscal year.

Ardent Health Partners Company Profile

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.